Author | Jack Arnold, MBBS, MRCP

Jack Arnold, MBBS, is a clinical research fellow working within Dr. Edward Vital's lupus team at the Leeds Centre of Rheumatic and Musculoskeletal Medicine. He graduated Distinction in Clinical Sciences from University College London in 2015 and has previously worked as a clinical tutor for Harris Manchester College Oxford. His work primarily focuses on systemic lupus erythematosus (SLE), antineutrophil cytoplasm antibodies (ANCA)-associated vasculitis and new approaches to the classification of autoimmune connective tissue diseases.

Articles

Lupus Nephritis: TULIP-LN Hints at a Blossoming Role for Anifrolumab

In the double blinded study, patients were randomized to receive anifrolumab (300mg monthly), an intensified regimen of 3 x 900mg doses followed by 300mg monthly, or standard of care therapy with mycophenolate mofetil and oral glucocorticoids.

Easy-BILAG: Fast Scoring, Faster Decisions in Lupus

"For many years we lacked access to novel therapeutics in SLE and our outcomes frequently reflected this," stated Jack Arnold, MBBS, MRCP. "However, with new targeted therapies, we appear to be entering a new era where treatment decisions will require more nuanced thought."